Entrada Therapeutics (NASDAQ:TRDA) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Entrada Therapeutics (NASDAQ:TRDA) posted its quarterly earnings data on Thursday. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.09, FiscalAI reports. The firm had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%.

Here are the key takeaways from Entrada Therapeutics’ conference call:

• Favorable safety and tolerability at 6 mg/kg: no serious adverse events, mostly mild–moderate AEs (headache most common), normal kidney markers, and all eight Cohort 1 participants have moved into the open‑label period.
• Treated participants showed a statistically significant and clinically meaningful improvement in Time To Rise (TTR) velocity versus placebo (mean change 0.08 rises/sec, ~3.5× the MCID), with benefits across most patients despite the small sample size.
• Pediatric PK was ~50% lower than in healthy adult volunteers and adult NHPs, producing modest exon skipping (~2.3% above baseline) and low dystrophin at biopsy (≈2.3% then ~6% at day 127), creating exposure and dosing uncertainty that must be addressed.
• Updated modeling using juvenile NHP data projects a dose‑dependent, potentially non‑linear increase in plasma AUC/exon skipping; management expects double‑digit dystrophin in Cohort 2 (12 mg/kg) and higher in Cohort 3, with Cohort 2 dosing underway and results due by year‑end 2026.
• Pipeline and timing: Entrada highlights multiple near‑term catalysts (Cohort 1 open‑label and Cohort 2 readouts by year‑end 2026, ELEVATE‑45 Cohort 1 mid‑2026, partner DM1 data H2 2026) and a reported cash runway into the third quarter of 2027.

Entrada Therapeutics Stock Down 0.5%

Shares of TRDA traded down $0.04 during trading hours on Friday, reaching $6.82. 1,315,493 shares of the company traded hands, compared to its average volume of 275,857. The company’s fifty day moving average price is $12.82 and its two-hundred day moving average price is $10.90. The company has a market capitalization of $264.56 million, a price-to-earnings ratio of -1.97 and a beta of -0.09. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $16.45.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Roth Mkm set a $10.00 target price on shares of Entrada Therapeutics in a research report on Friday. Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a research report on Wednesday, April 1st. They issued an “overweight” rating on the stock. Finally, Oppenheimer lifted their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.25.

Insider Activity

In other news, insider Natarajan Sethuraman sold 25,907 shares of Entrada Therapeutics stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.39, for a total transaction of $398,708.73. Following the sale, the insider owned 216,317 shares of the company’s stock, valued at approximately $3,329,118.63. The trade was a 10.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kory James Wentworth sold 2,500 shares of Entrada Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total transaction of $32,375.00. Following the sale, the chief financial officer directly owned 119,010 shares in the company, valued at $1,541,179.50. The trade was a 2.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 82,882 shares of company stock valued at $1,169,103. Corporate insiders own 9.49% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after acquiring an additional 90,339 shares in the last quarter. Millennium Management LLC boosted its stake in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after acquiring an additional 666,287 shares in the last quarter. Geode Capital Management LLC boosted its stake in Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after acquiring an additional 42,479 shares in the last quarter. State Street Corp boosted its stake in Entrada Therapeutics by 2.0% during the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock worth $5,230,000 after acquiring an additional 10,174 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Entrada Therapeutics by 14.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 362,786 shares of the company’s stock worth $3,729,000 after acquiring an additional 46,976 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Key Stories Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Entrada reported positive topline results from Cohort 1 of its ELEVATE-44-201 study in Duchenne muscular dystrophy, including favorable safety and tolerability, no serious adverse events, and a statistically significant improvement in Time to Rise velocity versus placebo. Article Title
• Positive Sentiment: The company said its cash, cash equivalents and marketable securities totaled about $255 million at quarter-end, with runway projected into Q3 2027, reducing near-term financing risk. Article Title
• Neutral Sentiment: Entrada beat earnings expectations for the quarter, posting a loss of $0.95 per share versus consensus for a larger loss, but revenue came in well below estimates at $0.88 million. Article Title
• Negative Sentiment: Despite the encouraging efficacy signal, the stock sold off sharply as traders weighed whether the early Duchenne data are strong enough to support the program’s valuation. Article Title
• Negative Sentiment: Q1 collaboration revenue fell sharply year over year and net loss widened, reinforcing concerns that Entrada remains heavily dependent on clinical execution to justify the current valuation. Article Title

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.